Ilan Ganot, the co-founder and chief executive of biotech firm Solid Biosciences, left a career in investment banking to start the company in 2013 in order to search for treatments, and perhaps cures, for Duchenne muscular dystrophy, a disease that afflicts his son.

It would be nice if, five years later, Ganot could report back stunning results that would have investors rushing to buy Solid’s stock. But biology is not fair. Instead, Solid is announcing results from the first six patients to take Solid’s experimental gene therapy for Duchenne, SGT-001, that fall below the expectations of Wall Street analysts and are likely to seriously disappoint holders of his stock.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • You left off the fact they’re not the most trustworthy company. The initial issues with the clinical hold around the IPO and now this. Don’t see how investors can trust them with the cash.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy